SpringerLink
Log in

Diagnostic value of dual-time point 68Ga-PSMA PET/CT image for benign and malignant lesions in patients with prostate cancer

  • Pelvis
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Objective

This study aimed to ascertain the diagnostic efficacy of routine 68Ga-PSMA imaging conducted 1 h post-injection, in conjunction with delayed imaging performed 3 h post-injection, for differentiating between benign and malignant lesions in prostate cancer (PCa) patients.

Methods

A retrospective assessment was undertaken on 44 prostate cancer patients who had undergone both routine and delayed 68Ga-PSMA PET/CT scans. Variations in SUVmax and SUVmean values in normal organs, primary prostate cancer sites, metastatic sites, and benign lesions were analyzed. Pathological examination and extended follow-ups were used to confirm all lesions.

Results

The study encompassed 44 patients, presenting 35 primary prostate cancer lesions, 44 metastatic lesions, and 30 benign lesions. Delayed imaging (3 h post-injection) demonstrated a decreasing trend in the SUVmax and SUVmean for the liver, blood, and spleen. Conversely, an increasing trend was observed for the parotid, lacrimal, and submandibular glands. For primary lesions, the SUVmax and SUVmean values were 17.63 ± 9.61 and 9.77 ± 5.18 during routine imaging, and 25.09 ± 15.11 and 14.05 ± 8.02 (P < 0.001) during delayed imaging. A comparable increase in SUVmax and SUVmean was seen in the delayed images for metastatic lesions when juxtaposed with routine images. Nevertheless, benign lesions displayed a decrease in SUVmax and SUVmean during delayed imaging when set against routine imaging (SUVmax: 3.56 ± 1.49 vs 2.93 ± 1.47, P = 0.001; SUVmean: 1.99 ± 0.87 vs 1.65 ± 0.87, P = 0.003).

Conclusion

Imaging using 68Ga-PSMA PET/CT at 3 h post-injection manifested a higher uptake and target-to-background uptake in most malignant prostate cancer lesions, but a diminished uptake in benign lesions. This observation can assist clinicians in distinguishing non-specific PSMA uptake in prostate cancer patients based on PSMA PET/CT image.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Pang L, Bo X, Wang J, Wang C, Wang Y, Liu G, Yu H, Chen L, Shi H, Liu H (2021) Role of dual-time point (18)F-FDG PET/CT imaging in the primary diagnosis and staging of hilar cholangiocarcinoma. Abdom Radiol (NY) 46:4138-4147. https://doi.org/10.1007/s00261-021-03071-2

    Article  PubMed  Google Scholar 

  2. Lee SW, Kim SJ(2022) Is delayed image of 18F-FDG PET/CT necessary for mediastinal lymph node staging in Non-Small cell lung cancer patients? CLIN NUCL MED 47:414-421. https://doi.org/10.1097/rlu.0000000000004110

    Article  PubMed  Google Scholar 

  3. Yu L, Huang S, Wu S, Yue J, Yin L, Lin Z(2023) Comparison of 18F-FDG PET/CT imaging with different dual time 18F-FDG PET/CT with forced diuresis in clinical diagnosis of prostate cancer. Medicine (Baltimore) 102:e32331. https://doi.org/10.1097/md.0000000000032331

    Article  CAS  PubMed  Google Scholar 

  4. Bundschuh RA, Lutje S, Bundschuh L, Lapa C, Higuchi T, Hartrampf PE, Gorin MA, Kosmala A, Buck AK, Pomper MG, Rowe SP, Essler M, Sheikh GT, Werner RA(2023) High interobserver agreement on PSMA PET/CT even in the absence of clinical data. CLIN NUCL MED 48:207-212. https://doi.org/10.1097/rlu.0000000000004524

    Article  PubMed  PubMed Central  Google Scholar 

  5. Riaz S, Priftakis D, Afaq A, Kayani I, Bomanji J(2023) 68 Ga-PSMA-Avid Intranasal Solitary Fibrous Tumor. CLIN NUCL MED 48:e184-e185. https://doi.org/10.1097/rlu.0000000000004572

    Article  PubMed  Google Scholar 

  6. Moreau A, Pretet V, Paquet E, Giraudet AL, Kryza D(2023) Intense diffuse lung uptake due to interstitial pneumopathy related to polyangiitis granulomata in 68 Ga-PSMA-11 PET/CT. CLIN NUCL MED 48:261-263. https://doi.org/10.1097/rlu.0000000000004408

    Article  PubMed  Google Scholar 

  7. Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T(2017) Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 44:960-968. https://doi.org/10.1007/s00259-017-3669-5

    Article  CAS  PubMed  Google Scholar 

  8. Hohberg M, Kobe C, Tager P, Hammes J, Schmidt M, Dietlein F, Wild M, Heidenreich A, Drzezga A, Dietlein M(2019) Combined early and late [(68)Ga]PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels. MOL IMAGING BIOL 21:558-566. https://doi.org/10.1007/s11307-018-1263-2

    Article  CAS  PubMed  Google Scholar 

  9. Kunikowska J, Kujda S, Krolicki L(2020) 68Ga-PSMA PET/CT in recurrence prostate cancer. Should we perform delayed image in cases of negative 60 minutes postinjection examination? CLIN NUCL MED 45:e213-e214. https://doi.org/10.1097/rlu.0000000000002966

    Article  PubMed  Google Scholar 

  10. Santhosh S, Jeeva G(2021) Delayed 68Ga-PSMA PET/CT Image-Guided biopsy for Low-Grade adenocarcinoma in benign prostatic hyperplasia. CLIN NUCL MED 46:e190-e192. https://doi.org/10.1097/rlu.0000000000003440

    Article  PubMed  Google Scholar 

  11. Kunikowska J, Pelka K, Tayara O, Krolicki L(2022) Ga-68-PSMA-11 PET/CT in patients with biochemical recurrence of prostate cancer after primary treatment with curative Intent-Impact of delayed imaging. J CLIN MED 11:3311. https://doi.org/10.3390/jcm11123311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, Kopka K, Haberkorn U(2017) The clinical impact of additional late PET/CT imaging with (68)Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J NUCL MED 58:750-755. https://doi.org/10.2967/jnumed.116.183483

    Article  CAS  PubMed  Google Scholar 

  13. Haupt F, Dijkstra L, Alberts I, Sachpekidis C, Fech V, Boxler S, Gross T, Holland-Letz T, Zacho HD, Haberkorn U, Rahbar K, Rominger A, Afshar-Oromieh A(2020) (68)Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. Eur J Nucl Med Mol Imaging 47:624-631. https://doi.org/10.1007/s00259-019-04548-5

    Article  CAS  PubMed  Google Scholar 

  14. Hoffmann MA, Buchholz HG, Wieler HJ, Rosar F, Miederer M, Fischer N, Schreckenberger M(2020) Dual-Time point [(68)Ga]Ga-PSMA-11 PET/CT hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel) 12:2788. https://doi.org/10.3390/cancers12102788

    Article  CAS  PubMed  Google Scholar 

  15. Berliner C, Steinhelfer L, Chantadisai M, Kroenke M, Koehler D, Pose R, Bannas P, Knipper S, Eiber M, Maurer T(2023) Delayed imaging improves lesion detectability in [(99m)Tc]Tc-PSMA-I&s SPECT/CT in recurrent prostate cancer. J NUCL MED 64:1036-1042. https://doi.org/10.2967/jnumed.122.265252

    Article  CAS  PubMed  Google Scholar 

  16. Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, Langsteger W: Multiphasic (68)Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng/mL(2020) A prospective study of 135 patients. J NUCL MED 61:1484-1490. https://doi.org/10.2967/jnumed.119.238071

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, West China Hospital of Sichuan University, No. 37. Guoxue Alley, Chengdu, 610041, Sichuan, People’s Republic of China

    Liu **ao, Minggang Su & Yuhao Li

Authors
  1. Liu **ao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Minggang Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuhao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuhao Li.

Ethics declarations

Conflict of interest

The authors have not disclosed any competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

**ao, L., Su, M. & Li, Y. Diagnostic value of dual-time point 68Ga-PSMA PET/CT image for benign and malignant lesions in patients with prostate cancer. Abdom Radiol (2024). https://doi.org/10.1007/s00261-024-04269-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00261-024-04269-w

Keywords

Search

Navigation